Agenda for Day One - Tuesday April 27, 2027Tuesday, 27 April 2027 - ET (Eastern Time, GMT-05:00)

Pharma has never faced this level of public and political scrutiny at once: pricing anger, tariff pressure, an upended pricing model and an industry fighting to be believed. Compliance isn't a spectator to that fight. It's the function that determines whether the industry earns its credibility back.

• Understand why trust, not enforcement risk, is becoming the real currency the industry trades in
• Explore what it takes for a compliance function to have a seat at the table when the business is under this kind of pressure
• Gain a candid, first-hand account of leading compliance through high-pressure public scrutiny

Every policy, every audit and every hard call made ultimately serves one person: the patient waiting for the medication to work, and to be able to trust it.

As a two-time breast cancer patient and advocate, Heidi combines authenticity, strategic insight, humor, and emotionally compelling storytelling to create presentations that resonate deeply with healthcare professionals, advocacy leaders, corporate audiences, and patient communities. Her work as a caregiver to other cancer patients is at the heart of her mission.

A candid look at what’s keeping today’s Chief Compliance Officers up at night, and how they’re adjusting their programs in real time as the ground shifts beneath them

• Define what's in scope for compliance departments in 2027 and where the boundaries should be drawn
• Break down operational silos to build a horizontal, interconnected governance framework across privacy, cybersecurity and evolving enterprise risks
• Navigate the tension between supporting innovation and mitigating risk when enforcement direction remains unclear

• Address on the evolving False Claims Act enforcement landscape facing pharmaceutical companies, highlighting recent trends in government investigations, settlements, and litigation, including through the operation of the DOJ-HHS FCA Working Group
• Remarks will offer actionable insights for compliance professionals navigating heightened scrutiny across the life sciences industry

A direct line to what DOJ is watching right now, from the officials setting enforcement priorities for the year ahead. Hear from DOJ:

• Current priorities regarding fraud, waste and abuse in life sciences
• Emerging risk areas, from AI governance to social media to other evolving compliance touchpoints
• Identify what's changing in compliance program guidance and how DOJ expects programs to keep pace

State enforcement has become its own compliance domain, with priorities and approaches that don't always mirror federal action

• Understand where state enforcement is most active right now across marketing, transparency, pricing and licensure
• How state-level requirements are creating compliance obligations that federal programs don't address

Hear directly from former prosecutors on how enforcement priorities translate into actual investigations and case decisions, including:

• Latest DOJ actions and investigations and what they signal for the industry
• Updates on healthcare fraud, FCPA and corporate enforcement priorities
• How recent DOJ guidance to prosecutors’ impact pharmaceutical companies
• Evolving landscape of False Claims Act litigation

• Review the seven core elements of an effective compliance framework
• Analyze program design requirements for start-up versus mature organizations
• Manage monitoring and auditing functions when operating with limited budgets
• Identify common early-stage compliance errors and practical methods to avoid them

• Identify where compliance and privacy responsibilities overlap across investigations, monitoring and third-party oversight
• Analyze privacy implications when deploying AI-enabled tools within an organization
• Establish practical framework steps to strengthen collaboration between compliance, privacy, legal and IT teams

Work through real AI governance dilemmas in small groups. Facilitators will guide discussions, capture insights and help you benchmark approaches against what other compliance teams are doing right now.

• Evaluating and approving AI use cases
• Define ownership across compliance, legal, privacy and IT
• Build flexible governance frameworks designed to mitigate risk while allowing responsible AI adoption
• Determine where to use AI to facilitate governance and controls over licenses and credentials

The job keeps expanding. The pressure keeps building. Join experienced compliance leaders as they share what's helped them stay effective without burning out

• Discover what separates compliance leaders who burn out from those who build long, durable careers
• Discuss practical habits for staying sharp and effective over the long run
• Learn from peers who’ve navigated the hardest stretches of the job